# Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

> **NCT00180895** · PHASE2 · TERMINATED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 40 (—)

## Conditions studied

- Burkitt Lymphoma

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00180895
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2006-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00180895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00180895, "Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00180895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*